Skip to content

Total debt at other companies

NeoGenomics logo
NeoGenomicsNEO
$66.29M+5.3%
Veracyte logo
VeracyteVCYT
$39.33M-22.1%
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
$208.18M-5.6%
Personalis, Inc. logo
Personalis, Inc.PSNL
$39M-6.2%
Tempus AI, Inc. logo
Tempus AI, Inc.TEM
$85.36M+49.8%
Guardant Health logo
Guardant HealthGH

Other financials

Income statement

See full
Revenue$25.6M+42.3%
Operating income-$6.2M+32.1%
Net income-$7.8M+29.8%
EPS (diluted)-$0.81+46.7%

Balance sheet

See full
Cash & equivalents$25.6M+45.3%
Total equity$9.1M-17.4%
Total assets$94.6M+9.7%

Cash flow

See full
Operating cash flow-$10.2M-18.2%
CapEx$81.0K+9.5%
Free cash flow-$10.2M-18.1%

Valuation

See full
Market cap$233.52M+476%
Enterprise value$279.56M+204%
P/S2.4×+1.9×

Profitability

See full
Operating margin-26%-7.5pp
Net margin-33.3%-9.3pp
FCF margin-26.8%-9.6pp

Returns & leverage

See full
Return on equity-316.5%
Debt / equity7.8×+2.2×
Current ratio2.8×+0.6×

Where this comes from

Calculated from Biodesix, Inc.’s reported figures.

Plus components not separately reported this period.

The official record: Biodesix, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biodesix, Inc.'s total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biodesix, Inc.'s total debt?
Biodesix, Inc. (BDSX) reported total debt of $71.61M in Q1 2026.
How has Biodesix, Inc.'s total debt changed year-over-year?
Biodesix, Inc.'s total debt increased by 15.0% year-over-year, from $62.27M to $71.61M.
What is the long-term trend for Biodesix, Inc.'s total debt?
Over 5 years (2020 to 2025), Biodesix, Inc.'s total debt has grown at a 35.5% compound annual growth rate (CAGR), from $15.93M to $72.85M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.